{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:08:08Z","timestamp":1781874488643,"version":"3.54.5"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n            <jats:title>Background and Objective:<\/jats:title>\n            <jats:p>Liver cancer is the second highest cause of cancer-related deaths worldwide. It is commonly treated with liver transplantation, where tacrolimus is typically used as an antirejection immunosuppressant. The purpose of this study was to evaluate the effect of tacrolimus time in therapeutic range (TTR) on liver cancer recurrence in liver transplant recipients and to compare the performance of TTRs calculated according to the target ranges recommended in published guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A total of 84 patients who underwent liver transplantation for liver cancer were retrospectively included. Tacrolimus TTR was calculated using linear interpolation from the date of transplantation until recurrence or the last follow-up according to target ranges recommended in the Chinese guideline and international expert consensus.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result:<\/jats:title>\n            <jats:p>Twenty-four recipients developed liver cancer recurrence after liver transplantation. The CTTR (TTR calculated according to the Chinese guideline) for the recurrence group was significantly lower than that of the nonrecurrence group (26.39% vs. 50.27%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), whereas the ITTR (TTR calculated according to the international consensus) was not significantly different between the two groups (47.81% vs. 56.37%, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.165). Multivariate survival analysis revealed that age, microvascular invasion, hepatocellular carcinoma, CTTR, and mean tacrolimus trough concentration were independent predictors of liver cancer recurrence after liver transplantation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>TTR predicts liver cancer recurrence in liver transplant recipients. The range of tacrolimus concentrations recommended in the Chinese guideline was more beneficial than that recommended in the international consensus for Chinese patients undergoing liver transplantation for liver cancer.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001119","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T18:00:09Z","timestamp":1686765609000},"page":"42-48","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Effect of Tacrolimus Time in Therapeutic Range on Postoperative Recurrence in Patients Undergoing Liver Transplantation for Liver Cancer"],"prefix":"10.1097","volume":"46","author":[{"given":"Qianying","family":"Lao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3533-643X","authenticated-orcid":false,"given":"Xuanyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; and"},{"name":"Nanjing Medical Center for Clinical Pharmacy, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; and"},{"name":"Nanjing Medical Center for Clinical Pharmacy, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; and"},{"name":"Nanjing Medical Center for Clinical Pharmacy, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaijun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China;"},{"name":"Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China; and"},{"name":"Nanjing Medical Center for Clinical Pharmacy, Nanjing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma\u2014evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","article-title":"Managements of recurrent hepatocellular carcinoma after liver transplantation: a systematic review","volume":"21","author":"de'Angelis","year":"2015","journal-title":"World J Gastroenterol."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3748\/wjg.v11.i10.1420","article-title":"Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth","volume":"11","author":"Schumacher","year":"2005","journal-title":"World J Gastroenterol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.jhep.2013.07.012","article-title":"Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma","volume":"59","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"J Hepatol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1111\/ajt.17021","article-title":"Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","volume":"22","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2022","journal-title":"Am J Transpl."},{"key":"R9-20250603","first-page":"8","article-title":"Diagnosis and treatment specification for immunosuppressive therapy and rejection of liver transplantation in China (2019 edition)","volume":"12","year":"2021","journal-title":"Organ Transplant."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.19102\/icrm.2017.080302","article-title":"Time in the therapeutic range (TTR): an overly simplified conundrum","volume":"8","author":"Reiffel","year":"2017","journal-title":"J Innov Card Rhythm Manag."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0038-1651587","article-title":"A method to determine the optimal intensity of oral anticoagulant therapy","volume":"69","author":"Rosendaal","year":"1993","journal-title":"Thromb Haemost."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1111\/ajt.14723","article-title":"Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients","volume":"18","author":"Ensor","year":"2018","journal-title":"Am J Transpl."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/FTD.0000000000000881","article-title":"Early monitoring and subsequent gain of tacrolimus time-in-therapeutic range may improve clinical outcomes after living kidney transplantation","volume":"43","author":"Yin","year":"2021","journal-title":"Ther Drug Monit."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/phar.2262","article-title":"Association between time-in-therapeutic tacrolimus range and early rejection after heart transplant","volume":"39","author":"Baker","year":"2019","journal-title":"Pharmacotherapy"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","author":"Davis","year":"2018","journal-title":"Am J Transpl."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/bcpt.13803","article-title":"Lower tacrolimus time in therapeutic range is associated with inferior outcomes in adult liver transplant recipients","volume":"132","author":"Song","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00000658-199705000-00004","article-title":"Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience","volume":"225","author":"Goss","year":"1997","journal-title":"Ann Surg."},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/ijc.26019","article-title":"Efficacy and safety of liver transplantation in patients with cholangiocarcinoma: a systematic review and meta-analysis","volume":"130","author":"Gu","year":"2012","journal-title":"Int J Cancer"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/jso.23289","article-title":"Transplantation versus resection for patients with combined hepatocellular carcinoma-cholangiocarcinoma","volume":"107","author":"Groeschl","year":"2013","journal-title":"J Surg Oncol."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/SLA.0000000000000494","article-title":"Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study","volume":"259","author":"Sapisochin","year":"2014","journal-title":"Ann Surg."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"10732748211011960","DOI":"10.1177\/10732748211011960","article-title":"Living donor liver transplantation: the optimal curative treatment for hepatocellular carcinoma even beyond Milan criteria","volume":"28","author":"Alim","year":"2021","journal-title":"Cancer Control"},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1245\/s10434-019-07227-9","article-title":"Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma","volume":"26","author":"Erstad","year":"2019","journal-title":"Ann Surg Oncol."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/lt.21738","article-title":"Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation","volume":"15","author":"Onaca","year":"2009","journal-title":"Liver Transpl."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation"},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"e14291","DOI":"10.1111\/ctr.14291","article-title":"Tacrolimus time-in-therapeutic range is associated with freedom from acute rejection and graft failure following intestinal transplantation","volume":"35","author":"Santeusanio","year":"2021","journal-title":"Clin Transpl."},{"key":"R28-20250603","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/TP.0000000000002913","article-title":"Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies","volume":"104","author":"Davis","year":"2020","journal-title":"Transplantation"},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.clinbiochem.2008.02.015","article-title":"Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique","volume":"41","author":"Ansermot","year":"2008","journal-title":"Clin Biochem."},{"key":"R30-20250603","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1038\/s41598-021-84868-5","article-title":"Association between medication adherence and intrapatient variability in tacrolimus concentration among stable kidney transplant recipients","volume":"11","author":"Ko","year":"2021","journal-title":"Sci Rep."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:06:32Z","timestamp":1748970392000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001119","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"2023-03-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}